Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $870.68 | 7 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| W. L. Gore & Associates, Inc. | $734.16 | 2 | $0 (2018) |
| Novo Nordisk Inc | $56.16 | 2 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $54.84 | 1 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $14.73 | 1 | $0 (2017) |
| Gilead Sciences Inc | $10.79 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $38.56 | 1 | Novo Nordisk Inc ($38.56) |
| 2018 | $806.60 | 4 | W. L. Gore & Associates, Inc. ($734.16) |
| 2017 | $25.52 | 2 | Novartis Pharmaceuticals Corporation ($14.73) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/05/2019 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $38.56 | General |
| Category: Obesity | ||||||
| 11/28/2018 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Obesity | ||||||
| 07/25/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $54.84 | General |
| Category: DIABETES | ||||||
| 03/19/2018 | W. L. Gore & Associates, Inc. | EXCLUDER AAA Endoprosthesis (Device) | Food and Beverage | In-kind items and services | $375.24 | General |
| Category: Devices | ||||||
| 03/19/2018 | W. L. Gore & Associates, Inc. | EXCLUDER AAA Endoprosthesis (Device) | Food and Beverage | In-kind items and services | $358.92 | General |
| Category: Devices | ||||||
| 03/01/2017 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/23/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $10.79 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 435 | 741 | $228,599 | $25,945 |
| 2022 | 17 | 1,355 | 1,951 | $1.0M | $82,034 |
| 2021 | 19 | 1,468 | 2,346 | $1.2M | $97,033 |
| 2020 | 28 | 1,955 | 3,126 | $1.2M | $95,129 |
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 85 | 89 | $27,399 | $6,853 | 25.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 118 | 118 | $137,498 | $6,166 | 4.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 79 | 81 | $16,512 | $4,545 | 27.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $13,827 | $3,296 | 23.8% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 19 | 310 | $4,460 | $2,247 | 50.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 20 | 20 | $6,364 | $1,618 | 25.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 30 | 39 | $1,313 | $327.60 | 25.0% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 16 | 16 | $8,856 | $307.84 | 3.5% |
| 93017 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) | Office | 2023 | 14 | 14 | $6,378 | $266.22 | 4.2% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 14 | 14 | $3,210 | $197.40 | 6.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 13 | 13 | $2,782 | $121.00 | 4.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 500 | 504 | $584,136 | $26,661 | 4.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 237 | 291 | $91,239 | $23,808 | 26.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 96 | 98 | $19,290 | $5,729 | 29.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 47 | 47 | $25,281 | $5,229 | 20.7% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 34 | 34 | $106,078 | $4,756 | 4.5% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2022 | 31 | 505 | $6,514 | $3,829 | 58.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 32 | 32 | $90,108 | $3,597 | 4.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 27 | 27 | $9,954 | $1,888 | 19.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $6,710 | $1,680 | 25.0% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2022 | 69 | 71 | $38,908 | $1,368 | 3.5% |
| 93017 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) | Office | 2022 | 53 | 53 | $23,784 | $1,129 | 4.7% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2022 | 56 | 56 | $12,660 | $928.26 | 7.3% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2022 | 27 | 28 | $6,328 | $456.09 | 7.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 26 | 28 | $5,952 | $283.42 | 4.8% |
About Dr. Timothy Logemann, MD
Dr. Timothy Logemann, MD is a Cardiovascular Disease healthcare provider based in Wausau, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/11/2005. The National Provider Identifier (NPI) number assigned to this provider is 1184626053.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Timothy Logemann, MD has received a total of $870.68 in payments from pharmaceutical and medical device companies, with $38.56 received in 2019. These payments were reported across 7 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($870.68).
As a Medicare-enrolled provider, Logemann has provided services to 5,213 Medicare beneficiaries, totaling 8,164 services with total Medicare billing of $300,141. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Practice Information
- Specialty Cardiovascular Disease
- Location Wausau, WI
- Active Since 08/11/2005
- Last Updated 01/17/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1184626053
Products in Payments
- EXCLUDER AAA Endoprosthesis (Device) $734.16
- Saxenda (Drug) $56.16
- JARDIANCE (Drug) $54.84
- ENTRESTO (Drug) $14.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Wausau
Dr. David Murdock, Md, MD
Cardiovascular Disease — Payments: $244,313
Dr. Mark Hoffmann, Md, MD
Cardiovascular Disease — Payments: $56,629
Ronnie Ortiz, Md, MD
Cardiovascular Disease — Payments: $33,551
Dr. Daniel Krause, Do, DO
Cardiovascular Disease — Payments: $3,351
Dr. Samer Jabbour, Md, MD
Cardiovascular Disease — Payments: $1,137
Dr. Paul Luetmer, Md, MD
Cardiovascular Disease — Payments: $926.48